pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,918 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT808Endpoints607BioPharma Dive231onclive165Fierce Biotech75BioSpace74raps32fda press20
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • The seeming inevitability of rising healthcare costs
    We’re getting our first signs of where healthcare costs are heading next year. According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges
    Endpoints · 1mo ago↗ source
  • STAT+: Abridge inks deals with Nvidia and Lilly
    Abridge announced new deals with Eli Lilly and Nvidia as it aims to gain an edge in a competitive market.
    STAT · 1mo ago↗ source
  • Summit pulls $500M share sale a day after announcing it
    The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.
    BioPharma Dive · 1mo ago↗ source
← prev
page 35 of 77
next →
globenewswire health20
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says
    DHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendr…
    Endpoints · 1mo ago↗ source
  • Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
    BioPharma Dive · 1mo ago↗ source
  • Summit withdraws $500M offering, citing 'market conditions'
    The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars. Summit Therapeutics ditched plans for a $500 million…
    Endpoints · 1mo ago↗ source
  • STAT+: A suspicious denial pattern in Medicare Advantage
    Major Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.
    STAT · 1mo ago↗ source
  • Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
    Plus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic review.”…
    Endpoints · 1mo ago↗ source
  • Camurus’ second CRL for acromegaly drug; Teva details workforce cuts
    Plus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer. T…
    Endpoints · 1mo ago↗ source
  • Novartis RNA drug acquired in $12B Avidity deal notches a trial win
    The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Novartis doubles down on molecular glue strategy
    Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Biopharma pay report: Top-paid CSOs, CMOs of 2025
    Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News lo…
    Endpoints · 1mo ago↗ source
  • Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
    Parabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...
    Endpoints · 1mo ago↗ source
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
    More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
    STAT · 1mo ago↗ source
  • STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
    A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, new data show.
    STAT · 1mo ago↗ source
  • STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
    Proving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.
    STAT · 1mo ago↗ source
  • HHS responds coolly to paper on alcohol risk
    Soda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
    Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib induce…
    Endpoints · 1mo ago↗ source
  • Neion Bio raises $23M Series A to make proteins from chicken eggs
    Neion Bio has secured an oversubscribed $23 million Series A to further develop its technology that uses chicken eggs to make active pharmaceutical ingredients for biologic drugs. The funding round…
    Endpoints · 1mo ago↗ source
  • Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
    BioPharma Dive · 1mo ago↗ source
  • Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
    In 2025, Elizabeth Selvin and her colleagues published in Nature Medicine for free. In 2026, it cost them $12,850, she writes.
    STAT · 1mo ago↗ source
  • Opinion: How long Covid’s scientific stalemate made it politically erasable
    Long Covid hasn’t disappeared. It’s just gone underground, writes Steven Phillips.
    STAT · 1mo ago↗ source
  • STAT+: Scientists see promise in NIH proposal to cap number of grants they receive
    Without easy access to leaders within a field or top-of-the-line lab equipment, principal investigators outside top universities often struggle to compete for grants from the NIH.
    STAT · 1mo ago↗ source
  • STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find
    Federal investigation finds Medicare Advantage insurers block rehab care for older adults, only to reverse denials on appeal.
    STAT · 1mo ago↗ source